NEW YORK, NY / ACCESSWIRE / May 12, 2015 / SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued a 2Q15 update note on DelMar Pharmaceuticals, Inc. (OTCQX: DMPI), a biotechnology company focused on proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments.
The note is available here: DMPI AACR Data Update. SeeThruEquity is an approved equity research contributor on Thomson First Call, CapitalIQ, FactSet, and Zack’s. The report will also be available on these platforms. We also contribute our estimates to Thomson Estimates, the leading estimates platform on Wall Street.
"We see many potential catalysts ahead for DMPI in 2015, and are encouraged by several announcements by the company during April, including development program updates from the Annual Meeting of the American Association for Cancer Research ("AACR"), which took place in Philadelphia, PA, from April 18 to April 22, 2015. We are reaffirming our 12 month price target of $4.53 per share," commented Ajay Tandon, CEO of SeeThruEquity.
Additional highlights from the update note are as follows:
Promising data shown for VAL-083 at AACR
DMPI presented promising data for three development programs associated with its lead product candidate, VAL-083, at AACR annual meeting in Philadelphia, PA. VAL-083 is a 'first-in-class' small molecule chemotherapeutic, which DelMar is developing as a potential new therapy for the treatment of GBM. VAL-083 is approved in China for the treatment of chronic myelogenous leukemia and lung cancer and has received orphan drug designation in Europe and the U.S. for the treatment of gliomas.
Promising data for treatment of GBM
Importantly, DMPI presented data from the VAL-083 study entitled "Dianhydrogalactitol inhibits the growth of glioma stem and non-stem cultures, including temozolomide-resistant cell lines, in vitro and in vivo," which investigated how cancer stem cells (CSC) and non-CSC panels respond in vitro to VAL-083 alone or in combination with irradiation (XRT). The study’s in vivo results demonstrated that VAL-083 is effective against GBM in significantly extending survival time in intracranial xenograft GBM models in a dose dependent manner, including in GBM xenografts that are traditionally resistant to temozolomide. We are encouraged by what clearly appears to be positive findings, and note that the data supports the company’s ongoing Phase 1/2 clinical study with VAL-083 as a treatment for refractory GBM in patients with recurrent disease. GBM represents a $1Bn annual market opportunity, and we see development milestones in this area as critical to the potential for material value creation at DMPI.
Please review important disclosures on our website at www.seethruequity.com.
About DelMar Pharmaceuticals, Inc.
DelMar Pharmaceuticals was founded in 2010 to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The Company's lead asset, VAL-083, is currently undergoing clinical trials in the United States as a potential treatment for refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. VAL-083 benefits from extensive clinical research sponsored by the U.S. National Cancer Institute (NCI), and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action. For more information, please visit http://www.delmarpharma.com.
About SeeThruEquity
SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and unbiased. We do not conduct any investment banking or commission based business. We are approved to contribute our research to Thomson Reuters One (First Call), CapitalIQ, FactSet, Zacks and distribute our research to our database of opt-in investors. We also contribute our estimates to Thomson Estimates, the leading estimates platform on Wall Street.
For more information visit www.seethruequity.com.
Contact:
Ajay Tandon
SeeThruEquity
(646) 495-0939
SOURCE: SeeThruEquity
